Can Nitazoxanide and/or other anti-viral medications be a solution to long COVID? Case report with a brief literature review
- PMID: 38028066
- PMCID: PMC10654558
- DOI: 10.1002/ccr3.8162
Can Nitazoxanide and/or other anti-viral medications be a solution to long COVID? Case report with a brief literature review
Abstract
Key clinical message: Findings here imply lingering of virus, SARS-CoV-2, in the body for months. Thus, Nitazoxanide and/or other anti-viral medications might be potential options to combat long COVID. This could transform treatment for long COVID patients globally.
Abstract: Long COVID or post-acute sequelae of COVID-19 (PASC) continues to affect many people even after a relatively mild acute illness. Underlying causes of PASC are poorly understood. There is no particular treatment or management program developed yet. Thus, the possibility of well-known, safe anti-viral medications use against PASC is proposed here.
Keywords: COVID‐19; Nitazoxanide; SARS‐CoV‐2; acyclovir; anti‐viral medication; herpesviruses; latent virus reactivation; long COVID; post‐acute sequelae (PASC); shingles.
© 2023 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.
Conflict of interest statement
None.
Figures


References
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous